Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRAME T-cell engager
- Development stage
- Preclinical
- Lead developer
- MyriO Tx
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
MyriO Tx's PRAME T-cell engager is a preclinical bispecific antibody therapy designed to treat solid tumors, specifically ovarian cancer and melanoma. Developed using the proprietary ReD platform, the drug targets the cancer-testis antigen PRAME (Preferentially Expressed Antigen in Melanoma) when presented as peptide-HLA (pHLA) complexes on the surface of tumor cells. By binding both PRAME and T cells (typically via CD3), the engager facilitates the recruitment and activation of T cells to selectively eliminate PRAME-expressing malignant cells. This approach allows for the targeting of intracellular antigens that are typically inaccessible to standard antibody therapies.
- Other names
- PRAME T cell engagerPRAME bispecific T-cell engagerMyriO PRAME T-cell engager
02
Targets
PRAME (Preferentially expressed antigen in melanoma)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on PRAME T-cell engager.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRAME T-cell engager.